R-EPOCD与R-CDOP方案对初治双表达淋巴瘤效果  

EFFECT OF R-EPOCD VERSUS R-CDOP REGIMEN IN THE TREATMENT OF TREATMENT-NAIVE DOUBLE-EXPRESSOR LYMPHOMA

作　　者：牛文验 肖淑欣[1] 荆凡静[1] 宋伟[1] 王亚文[1] 薛宏伟[1] NIU Wenyan;XIAO Shuxin;JING Fanjing;SONG Wei;WANG Yawen;XUE Hongwei(Lymphoma Department,The Affiliated Hospital of Qingdao University,Qingdao 266555,China)

机构地区：[1]青岛大学附属医院淋巴瘤科,山东青岛266555

出　　处：《青岛大学学报（医学版）》2021年第1期64-68,共5页Journal of Qingdao University(Medical Sciences)

基　　金：希思科-齐鲁肿瘤研究基金项目(Y-Q201801-078)。

摘　　要：目的比较R-EPOCD(利妥昔单抗、依托泊苷、泼尼松、长春新碱、环磷酰胺、多柔比星脂质体)与R-CDOP方案(利妥昔单抗、环磷酰胺、多柔比星脂质体、长春新碱、泼尼松)治疗双表达淋巴瘤(DEL)效果及不良反应。方法收集我院收治的33例DEL病人的临床资料,17例接受R-EPOCD方案化疗,16例接受R-CDOP方案化疗,比较两种方案治疗效果及不良反应。结果可评估最终疗效病人28例,R-EPOCD组(n=13)的完全缓解率(CR)较R-CDOP组(n=15)高(84.6%vs 60.0%),但差异无显著性(χ^2=2.068,P>0.05)。中位随访时间13个月,两组病人的总生存率(OS)和无进展生存率(PFS)比较差异无统计学意义(P>0.05)。两组Ⅲ/Ⅳ度中性粒细胞计数降低发生率比较差异无统计学意义(P>0.05)。结论R-EPOCD治疗DEL病人CR率不低于R-CDOP,不良反应可以耐受。Objective To compare the effects and adverse reactions of R-EPOCD(rituximab,etoposide,prednisone,vincristine,cyclophosphamide,and liposomal doxorubicin)and R-CDOP(rituximab,cyclophosphamide,liposomal doxorubicin,vincristine,and prednisone)regimens in the treatment of double-expressor lymphoma(DEL).Methods Clinical data were collected from 33 patients with DEL who were admitted to our hospital,among whom 17 received chemotherapy with R-EPOCD regimen and 16 with R-CDOP regimen.The therapeutic effects and adverse reactions of the two regimens were compared.Results The final therapeutic effects were evaluable in 28 patients.The complete remission(CR)rate of the R-EPOCD group(n=13)was higher than that of the R-CDOP group(n=15),but the difference was not significant(84.6%vs 60.0%,χ^2=2.068,P>0.05).There were no significant differences in overall survival and progression-free survival at a median follow-up of 13 months as well as in the incidence of grade 3/4 neutropenia between the two groups(P>0.05).Conclusion Compared with R-CDOP,the R-EPOCD regimen yields a higher CR rate with tolerable adverse reactions.

关 键 词：淋巴瘤 大B细胞 弥漫性 药物疗法 治疗结果 药物相关性副作用和不良反应 

分 类 号：R733.4[医药卫生—肿瘤]